GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Cognition Inc (OTCPK:ACOGF) » Definitions » Notes Receivable

Alpha Cognition (Alpha Cognition) Notes Receivable : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Alpha Cognition Notes Receivable?

Alpha Cognition's Notes Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.


Alpha Cognition Notes Receivable Historical Data

The historical data trend for Alpha Cognition's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Cognition Notes Receivable Chart

Alpha Cognition Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Notes Receivable
- - - -

Alpha Cognition Quarterly Data
Jan20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Alpha Cognition Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Alpha Cognition Notes Receivable Related Terms

Thank you for viewing the detailed overview of Alpha Cognition's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Alpha Cognition (Alpha Cognition) Business Description

Traded in Other Exchanges
Address
301 - 1228 Hamilton Street, Vancouver, BC, CAN, V6B 6L2
Alpha Cognition Inc is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, and Cognitive Impairment with Mild Traumatic Brain Injury (mTBI) for which there are limited or no treatment options. The Company is focused on the development of ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and completed an NDA filing to the FDA in September 2023. The company anticipates an FDA approval in mid-2024. The Company's ALPHA-1062 development program is primarily focused on clinical and regulatory development, Chemistry, Manufacturing and Control (CMC) development, and commercial readiness.